[go: up one dir, main page]

FI20041489A0 - Menetelmä atorvastatiini kalsium valmistamiseksi amorfisessa muodossa - Google Patents

Menetelmä atorvastatiini kalsium valmistamiseksi amorfisessa muodossa

Info

Publication number
FI20041489A0
FI20041489A0 FI20041489A FI20041489A FI20041489A0 FI 20041489 A0 FI20041489 A0 FI 20041489A0 FI 20041489 A FI20041489 A FI 20041489A FI 20041489 A FI20041489 A FI 20041489A FI 20041489 A0 FI20041489 A0 FI 20041489A0
Authority
FI
Finland
Prior art keywords
amorphous form
atorvastatin calcium
preparing atorvastatin
preparing
calcium
Prior art date
Application number
FI20041489A
Other languages
English (en)
Swedish (sv)
Other versions
FI120344B (fi
FI20041489L (fi
Inventor
Yatendra Kumar
Saridi Madhava Dileep Kumar
Swargam Sathyanarayana
Original Assignee
Ranabxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranabxy Lab Ltd filed Critical Ranabxy Lab Ltd
Publication of FI20041489A0 publication Critical patent/FI20041489A0/fi
Priority to EP05077109A priority Critical patent/EP1659110A1/en
Publication of FI20041489L publication Critical patent/FI20041489L/fi
Application granted granted Critical
Publication of FI120344B publication Critical patent/FI120344B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI20041489A 2004-03-17 2004-11-19 Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi FI120344B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05077109A EP1659110A1 (en) 2004-03-17 2005-09-16 Process for the production of atorvastatin calcium un amorphous form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN491DE2004 2004-03-17
IN491DE2004 2004-03-17

Publications (3)

Publication Number Publication Date
FI20041489A0 true FI20041489A0 (fi) 2004-11-19
FI20041489L FI20041489L (fi) 2006-07-20
FI120344B FI120344B (fi) 2009-09-30

Family

ID=33516010

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20041489A FI120344B (fi) 2004-03-17 2004-11-19 Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi

Country Status (17)

Country Link
US (1) US7994343B2 (fi)
EP (3) EP1577297A1 (fi)
CN (2) CN1942439B (fi)
AR (1) AR048271A1 (fi)
AT (1) ATE545629T1 (fi)
AU (2) AU2004317570B2 (fi)
CA (3) CA2627940A1 (fi)
CY (1) CY1112583T1 (fi)
DK (1) DK1727795T3 (fi)
ES (1) ES2381473T3 (fi)
FI (1) FI120344B (fi)
MY (1) MY147435A (fi)
NO (1) NO330092B1 (fi)
PL (1) PL1727795T3 (fi)
PT (1) PT1727795E (fi)
SI (1) SI1727795T1 (fi)
WO (1) WO2005092852A1 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1577297A1 (en) * 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Process for the production of atorvastatin calcium in amorphous form
ES2586561T3 (es) * 2004-07-16 2016-10-17 Lek Pharmaceuticals D.D. Productos de degradación oxidativa de atorvastatina calcio
JP2008510798A (ja) * 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
GB0613566D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
EP1928823B1 (en) 2005-08-15 2014-10-08 Arrow International Limited Process for preparing crystalline sodium salt of ATORVASTATIN
GB0613567D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
EP1924555B1 (en) 2005-08-15 2014-10-08 Arrow International Limited Process for the preparation of crystalline sodium atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
CN101205209B (zh) * 2007-12-25 2010-06-02 浙江新东港药业股份有限公司 一种阿伐他汀中间体的精制方法
EP2075246A1 (en) * 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101468963B (zh) * 2007-12-28 2012-09-19 石药集团中奇制药技术（石家庄）有限公司 一种无定形阿伐他汀钙的制备方法
KR100850558B1 (ko) * 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
US8115015B2 (en) 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HUE030160T2 (en) * 2010-04-19 2017-05-29 Dsm Sinochem Pharm Nl Bv Preparation of atorvastatin with low dietary contamination
CN102127060B (zh) * 2010-12-17 2013-12-04 蚌埠丰原医药科技发展有限公司 一种阿托伐他汀钙中间体的制备方法
CN102070504A (zh) * 2010-12-23 2011-05-25 蚌埠丰原医药科技发展有限公司 阿托伐他汀钠的制备方法
CN102070505B (zh) * 2011-01-28 2012-01-11 海南美大制药有限公司 阿托伐他汀钙化合物及其新制法
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
WO2017060885A1 (en) * 2015-10-09 2017-04-13 Laurus Labs Private Limited An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof
CN106478591B (zh) * 2016-09-30 2018-11-13 北京嘉林药业股份有限公司 一种阿托伐他汀缩合物中间体的拆分方法
CN106432033B (zh) * 2016-10-21 2018-07-27 江苏阿尔法药业有限公司 一种无定形阿托伐他汀钙的制备方法
CN108033899B (zh) * 2017-12-06 2020-04-10 浙江科技学院 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法
CN109232355A (zh) * 2018-10-09 2019-01-18 河南师范大学 一种有效去除阿托伐他汀钙粗品中杂质阿托伐他汀缩合物的方法
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法
CN110563628B (zh) * 2019-08-26 2022-04-05 北京嘉林药业股份有限公司 一种双釜制备高纯度和单分散i晶型阿托伐他汀钙的结晶方法
CN110776451B (zh) * 2020-01-02 2020-05-22 湖南迪诺制药股份有限公司 一种i晶型阿托伐他汀钙的制备方法
CN113695307B (zh) * 2020-05-20 2022-12-02 天津嘉林科医有限公司 一种盛放阿托伐他汀钙的玻璃器皿的清洗方法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
DE69324504T2 (de) 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128864A (en) 1995-07-17 2007-10-31 Warner Lambert Co Atorostatin II form crystals and its hydrates, methods of preparation and pharmaceutical preparations containing it
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (fi) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
SK16982002A3 (sk) 2000-06-09 2003-04-01 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozícia a liečivý prípravok túto kompozíciu obsahujúci
AU4150602A (en) 2000-11-03 2002-06-03 Teva Pharma Atorvastatin hemi-calcium form vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057225A2 (en) 2000-12-18 2002-07-25 Merck & Co., Inc. Thrombin inhibitors
CA2622477A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (fi) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
MXPA03010266A (es) 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
RU2304139C2 (ru) 2001-07-30 2007-08-10 Д-р Редди'с Лабораторис Лтд Кристаллические формы vi и vii кальциевой соли аторвастатина
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CA2479005C (en) 2002-03-18 2012-05-22 Biocon Limited Amorphous atorvastatin calcium or pravastatin sodium hmg-coa reductase inhibitors of desired particle size
AU2002356423A1 (en) 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
HU227041B1 (en) 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
EP1577297A1 (en) * 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Process for the production of atorvastatin calcium in amorphous form
CN101124230A (zh) 2004-09-28 2008-02-13 特瓦制药工业有限公司 制备基本无杂质的阿托伐他汀钙形式的方法

Also Published As

Publication number Publication date
EP1727795B1 (en) 2012-02-15
CY1112583T1 (el) 2016-02-10
AU2004317570B2 (en) 2011-01-06
EP1727795A1 (en) 2006-12-06
US20100197941A1 (en) 2010-08-05
ES2381473T3 (es) 2012-05-28
CA2666359A1 (en) 2005-10-06
AU2010249166B2 (en) 2012-02-09
CA2627940A1 (en) 2005-10-06
CN1942439B (zh) 2011-12-21
EP1577297A1 (en) 2005-09-21
ATE545629T1 (de) 2012-03-15
EP1659110A1 (en) 2006-05-24
CN1946688A (zh) 2007-04-11
CA2560252C (en) 2009-08-04
US7994343B2 (en) 2011-08-09
FI120344B (fi) 2009-09-30
SI1727795T1 (sl) 2012-05-31
NO330092B1 (no) 2011-02-14
DK1727795T3 (da) 2012-04-16
NO20045037D0 (no) 2004-11-19
PT1727795E (pt) 2012-04-11
AU2010249166A1 (en) 2010-12-23
WO2005092852A1 (en) 2005-10-06
AR048271A1 (es) 2006-04-12
NO20045037L (no) 2005-09-19
AU2004317570A1 (en) 2005-10-06
MY147435A (en) 2012-12-14
CA2560252A1 (en) 2005-10-06
FI20041489L (fi) 2006-07-20
PL1727795T3 (pl) 2012-06-29
CN1942439A (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
FI20041489A0 (fi) Menetelmä atorvastatiini kalsium valmistamiseksi amorfisessa muodossa
IL187578A0 (en) Process for preparing pure amorphous rosuvastatin calcium
ZA200702965B (en) Process for forming amorphous atorvastatin
PL2818555T3 (pl) Sposób wytwarzania zasadowej substancji
ZA200705155B (en) Process for making a germanium-zeolite
IL184349A0 (en) Amorphous lercanidipine hydrochloride
IL183239A0 (en) Process for preparing amorphous valsartan
PL3266575T3 (pl) Sposób wytwarzania kształtki
EP1793815A4 (en) AMORPHES ATORVASTATINCALCIUM
TWI368261B (en) Method to form a film
PL1899297T3 (pl) Zofenopryl wapnia w postaci polimorficznej c
ZA200608632B (en) Process for forming amorphous atorvastatin calcium
NO20052658D0 (no) Fremgangsmate for oppstarting av en flytendegjoringsprosess
EP1856101A4 (en) PROCESS FOR PREPARING AMORPHENE SALTS
PL1858851T3 (pl) Sposób otrzymywania amorficznej lerkanidypiny
IL181075A0 (en) Process for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine
GB0510457D0 (en) Method for activating a sex toy
FI20065594L (fi) Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
FI20065595L (fi) Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
EP1948637A4 (en) PROCESS FOR AMORPHES ESOMEPRAZOLE
ITMI20061576A1 (it) Process for preparing amorphous lercanidipine hudrochloride
SI1641438T1 (sl) Postopek za pripravo amorfne oblike zdravila
ITMI20061577A1 (it) Process for preparing amorphous lercanidipine hydrochloride
ITBO20040397A1 (it) Bauletto per ciclo
FI20055050A0 (fi) Menetelmä peruskappaleen muodostamiseksi

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120344

Country of ref document: FI

MM Patent lapsed